INTRODUCTION
============

Silent brain infarction (SBI) is defined as an asymptomatic infarction, and is often incidentally detected on computed tomography (CT) or magnetic resonance imaging (MRI) in subjects with no history of stroke. It is relatively common in the elderly, and the incidence of SBI significantly increases with older age.[@B1],[@B2] The presence of SBI has been identified as an independent risk factor for the development of symptomatic infarction.[@B3]-[@B7] Therefore, population-based studies have been performed to identify risk factors for SBI, as well as factors that promote the progression of SBI to other symptomatic cerebrovascular disorders.[@B8]

It has been suggested that hyperhomocysteinemia is a risk factor for a number of occlusive vascular diseases, including SBI.[@B2],[@B9]-[@B12] The methylenetetrahydrofolate reductase (*MTHFR*) gene has genetic variants (677C\>T and 1298A\>C) that reduce the enzyme activity, thereby elevating plasma total homocysteine (tHcy) levels.[@B13]-[@B17] Most previous studies have concentrated on the *MTHFR* 677C\>T polymorphisms associated with stroke, cancer, birth defects, recurrent abortion, and cardiovascular disorders.[@B15],[@B18]-[@B24] However, only a few studies have been conducted to assess the association of a second common polymorphism, 1298A\>C, with ischemic stroke, cancer, and heart disease.[@B25]-[@B31] No association studies of the *MTHFR* 1298A\>C polymorphism with SBI were conducted.

Therefore, we conducted this study to investigate the association between the *MTHFR* 677C\>T and 1298A\>C polymorphisms and the risk of SBI in a Korean population.

MATERIALS AND METHODS
=====================

Patients
--------

The study population was composed of 264 patients (121 males, 143 females; mean age ± SD, 62.26 ± 11.95 years) with SBI and 227 control subjects (109 males, 118 females; mean age ± SD, 59.62 ± 11.67 years). Patients with SBI were enrolled and recruited between July 2000 and February 2005 in the Bundang CHA Hospital.

Patients with known history of stroke or cardiovascular diseases were excluded. MRI was performed on a 1.5-T superconducting magnet (Siemens Magnetom Symphony, Erlangen, Germany). Transverse T1-weighted, T2-weighted, and FLAIR images were obtained with a slice thickness of 7 mm. The diagnosis of SBI was made as follows: 1) spotty areas ≥ 3 mm in diameter in the area supplied by deep perforating arteries, showing high intensity in the T2 and FLAIR images and low intensity in the T1 image; 2) absence of neurological signs and symptoms corresponding to the MRI lesions; 3) no history of clinical stroke, including transient ischemic attack. Small punctate hyperintensity lesions (1 to 2 mm in diameter) were more likely to represent a dilated perivascular space, and were not considered in the present study. The diagnosis of SBI was made when two independent researchers agreed on the diagnosis.

Controls (n = 227), which showed no evidence of SBI on MRI, were recruited from subjects who visited the hospital for a health examination. They had no past history of stroke or cardiovascular disease. Our subjects were classified into two age groups: subjects aged \< 65 years and subjects aged ≥ 65 years. Baseline demographic data and a history of conventional vascular risk factors were obtained from each control subject. Detailed information on medical history was obtained from all study subjects. The institutional review committee of Bundang CHA Hospital approved this study in June 2000. Informed consent was obtained from all participants.

Biochemical measurements
------------------------

Overnight fasting (12 hours) blood samples were collected in EDTA-containing tubes and immediately placed on ice. After centrifugation at 2000 rpm for 15 minutes, plasma samples were kept at -20℃ until analysis. Plasma total homocysteine (tHcy) levels were determined by fluorescence polarization immunoassay (IMx, Abbott Laboratories, North Chicago, IL, USA).

Genetic analysis
----------------

Genomic DNA was extracted from leukocytes by using a DNA extraction kit (QIAmp blood kit, Qiagen) according to the protocol of the manufacturer. *MTHFR* 677C\>T and 1,298A\>C genotypes were identified as described previously.[@B15],[@B17] Regions containing the two polymorphisms were amplified separately. For the nucleotide 677 polymorphism, the primers 5\'-GCA CTT GAA GAG AAG GTG TC-3\' (forward) and 5\'-AGG ACG GTG CGG TGA GAG TG-3\' (reverse) were used, and for the nucleotide 1298 polymorphism, 5\'-CTT TGG GGA GCT GAA GGA CTACTA C-3\' (forward) and 5\'-CAC TTT GTG ACC ATT CCG GTT TG-3\' (reverse) were used. Human genomic DNA (200 ng) was amplified with 100 pmol of each forward and reverse primer, 1.5 mM MgCl~2~, 0.2 M each deoxynucleotide triphosphate, and 1 unit Taq polymerase (Takara, Madison, Wisconsin, USA) in a total volume of 100 uL. PCR conditions were as follows: denaturation at 94℃ for 5 min, followed by 35 cycles at 94℃ for 30s, 51℃ for 30s, and 72℃ for 30s, and a final terminal elongation at 72℃ for 5 min. PCR products were digested with HinfI (for nucleotide 677) or Fnu4HI (for nucleotide 1,298) for 2 hours at 37℃.

Amplification success was monitored by 3.0% agarose electrophoresis. For the nucleotide 677, an undigested PCR product (203 bp) indicated a homozygous wild-type, three bands of 203, 173, and 30 bp indicated the heterozygous genotype, and two bands of 170 and 30 bp indicated the homozygous genotype. For nucleotide 1,298, a single band of 138 bp indicated a wild-type, and two fragments of 119 and 19 bp indicated the homozygous genotype.

Statistical analysis
--------------------

To estimate the relative risk for SBI for the various genotypes, an odds ratio (OR) and 95% confidence interval (CI) were calculated. Differences between the patient and control groups were assessed by the χ^2^ test for categorical variables (sex, hypertension, and diabetes mellitus) and the two-sample t-test for continuous variables (age and tHcy level). For the multivariate analysis, logistic regression analysis was used to adjust for possible confounders, including age, sex, hypertension, and diabetes mellitus. The plasma tHcy levels differences between patients and controls were examined by analysis of covariance (ANCOVA), adjusted for age and sex. Haplotypes analysis was performed using case-control haplotype analysis-permutation test.

The analysis was performed using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, CA, USA), Stats-Direct Statistical Software Version 2.4.4 (StatsDirect Ltd., Altrincham, UK), Medcalc (version 7.4 for Windows; Frank. Schoonjans, Belgium) and SAS 9.1 for Windows (SAS Institute Inc., Cary, NC, USA).

RESULTS
=======

[Table 1](#T1){ref-type="table"} shows the distributions of clinical characteristics of patients with SBI and control subjects. Patients had a significantly higher prevalence of hyperlipidemia, but not of diabetes mellitus or hypertension, compared to the controls. To evaluate the pure effects of the *MTHFR* genotypes on SBI, we adjusted the OR for age, sex, hypertension, and diabetes mellitus. Significant elevation of pHcy concentrations was found in patients compared to controls (11.34 ± 6.385 µmol/L vs. 9.676 ± 3.959 µmol/L, *p* = 0.0007).

In this study, all of the study populations were in Hardy-Weinberg equilibrium. The 1298AC genotype was found to show a significant 1.734-fold increased risk of developing SBI (AOR = 1.734, 95% CI = 1.13-2.66), and 1298AC + CC genotypes were significantly associated with a 1.825-fold increased risk for SBI (AOR = 1.825, 95% CI = 1.20-2.78), whereas for the *MTHFR* 677C\>T polymorphisms in SBI patients there were no statistically significant differences in the effects of the *MTHFR* genotypes on SBI between the patients and the controls ([Table 2](#T2){ref-type="table"}).

For the *MTHFR* 1298A\>C polymorphisms, significant difference was found in terms of the risk for SBI in females (AC, AOR = 2.205, 95% CI = 1.11-3.70; AC + CC, AOR = 2.106, 95% CI = 1.16-3.83). When this population was separated into two age groups, 1298AC + CC genotypes showed a 1.789-fold increased risk for SBI in patients aged \< 65 years, and this relationship showed statistical significance (AOR = 1.789; 95% CI = 1.05-3.05) ([Table 3](#T3){ref-type="table"}). In addition, when stratified by age of 55 years, genotype frequencies were significantly different for SBI in females and older than 55 years (in females, AC, AOR = 2.025, 95% CI = 1.11-3.70, AC + CC, AOR = 2.106, 95% CI = 1.16-3.83; in ≥ 55 years, AC, AOR = 1.987, 95% CI = 1.18-3.34, AC + CC, AOR = 2.088, 95% CI = 1.25-3.50). *MTHFR* 677C\>T polymorphism in subgroup analysis of the SBI patients was not statistically significant such as genders or age groups (*p* \> 0.05; data not shown).

As seen in [Table 2](#T2){ref-type="table"}, nine combinations are possible. However, no individual with 677CT/1298CC, 677TT/1298AC, and 677TT/1298CC was detected.[@B32]-[@B34] The compound genotype of 677CC/1298AC showed a 2.689-fold increased risk for SBI (AOR=2.689, 95% CI = 1.26-5.76), and the compound genotype of 677CT/1298AC revealed a 2.604-fold increased risk for SBI (AOR = 2.604, 95% CI = 1.29-5.25). The 677TT/1298AA compound genotype was approximately 2.3 times more prone to developing SBI than the controls (AOR = 2.289; 95% CI = 1.19-4.42) ([Table 2](#T2){ref-type="table"}).

Four haplotypes are possible, but the *677T-1298C* haplotype was not present in our patient population. When the cases of SBI were compared with the controls, there were significant differences in the distribution frequency between cases and controls for the *677C-1298A* (*p* = 0.006) and *677C-1298C* (*p* = 0.009) haplotypes ([Table 4](#T4){ref-type="table"}). The *677C-1298A* haplotype showed a lower frequency in patients with SBI than in the controls. However, the *677C-1298C* haplotype was more frequently observed in patients than in controls.

The tHcy levels were higher in patients with heterozygous 677CT and 677CT + TT genotypes compared to the corresponding control population. A statistically significant elevation of tHcy levels was observed for genotypes 1298AA, 1298AC, and 1298AC + CC. The tHcy levels were higher in patients with 1298CC than in the controls, but did not reach statistical significance due to the limited number of cases with this genotype. In combined genotypes, the tHcy levels were significantly higher in patients with 677CT/1298AC than in the controls, and 677TT/1298AA genotypes showed an increase in tHcy levels compared to controls, with marginal significance ([Table 5](#T5){ref-type="table"}).

DISCUSSION
==========

Hyperhomocysteinemia is a well-known risk factor for vascular diseases, including stroke, and it has been suggested that this condition may be a risk factor for the development of SBI.[@B8],[@B9],[@B12] The tHcy levels can potentially be elevated by either environmental (including diet) and/or genetic factors.

The common polymorphism in the *MTHFR* 677C\>T can reduce enzyme activity, resulting in hyperhomocysteinemia, and can also increase the risks of cardiovascular diseases, certain types of cancer, and birth defects.[@B31] The *MTHFR* 1298A\>C polymorphism has also been found to reduce *MTHFR* enzyme activity, to a lesser extent than those with the 677C\>T mutation, but conflicting results have been reported with respect to the association between 1298A\>C polymorphism and tHcy levels. It has been reported that the *MTHFR* 1298A\>C polymorphism may be associated with ischemic stroke, and may also play a protective role against colorectal cancer and acute lymphocytic leukemia.[@B35]

In this study, the tHcy levels were significantly higher in patients with *MTHFR* 677TT than in patients with other *MTHFR* 677C\>T genotypes, while no correlation between tHcy and *MTHFR* 1298A\>C genotypes was found. Recent studies have demonstrated that 1298A\>C, in combination with 677C\>T, may be associated with decreased MTHFR activity resulting in hyperhomocysteinemia, which is consistent with our results ([Table 5](#T5){ref-type="table"}).[@B14],[@B36]-[@B38] *MTHFR* 1298AC and *MTHFR* 1298AC + CC individuals were more prone to an increased risk for SBI than the corresponding controls, while the polymorphism of 677C\>T at the *MTHFR* gene did not significantly influence the risk of SBI. When combined with the 1298A\>C genotypes, however, we found that *MTHFR* 677C\>T could have an additive effect on the variation at the *MTHFR* 1298A\>C gene, because individuals carrying the predisposing variants (677CC/1298AC, 677CT/1298AC, 677TT/1298AA) at the two loci showed a higher risk of the development of SBI than any AOR individuals registered for *MTHFR* 1298A\>C genotypes ([Table 2](#T2){ref-type="table"}).

Furthermore, we investigated the associations between SBI and allele haplotypes. The C-C haplotype increased the risk of SBI, whereas the C-A haplotype, a normal allele-combined haplotype, decreased the risk of the development of SBI. These results suggested that 1298A\>C may be a more important genetic risk factor for SBI than 677C\>T, and the *MTHFR 1298C* allele-containing haplotype may have the potential to be a predictive marker of the development of SBI in the Korean population.

However, the relationships between *MTHFR* polymorphisms and multifactorial diseases, especially cardiovascular disease and stroke, remain highly controversial, and genetic influences of *MTHFR* polymorphisms have not been observed in a number of populations. There was a racial difference in the frequency of the *1298C* allele: Canadian, 0.36, French, 0.33, English, 0.32, German, 0.30, American, 0.29, South African, 0.21, Japanese, 0.19, Chinese, 0.17, Korean, 0.125, Korean, 0.178, and Korean, 0.163.[@B25],[@B28],[@B32],[@B36],[@B37],[@B39]-[@B42] From the literature, the *MTHFR 1298C* allele frequency was 0.125 to 0.178 in the Korean populations. The 1298CC genotype is present at a much lower frequency, at 1.4-3.7%, in Asian populations, compared to 7.2-12.6% in the Caucasian population; this information is consistent with our results.[@B25],[@B27]-[@B29],[@B32],[@B36],[@B39] In the current study, the frequencies of the 1298AA, AC, and CC genotypes in the control group were 77.8%, 21.8%, and 0.4%, respectively. The corresponding frequencies in the patient group were 67.8%, 30.3%, and 1.9%, respectively. The frequency of the *MTHFR 1298C* allele was significantly higher in the SBI patients than in the controls. These findings indicate that there are ethnic variations in terms of the 1298A\>C polymorphism, as well as a difference in the occurrence of SBI between the Asian population and the Caucasian population. It is conceivable that the contributions of *MTHFR* polymorphisms to SBI may vary in different ethnic groups.

In addition, no statistically significant difference in the risk for SBI was found between *MTHFR* genotypes in subjects over 65 years of age. We found that the 1298AC and 1298AC + CC genotypes showed an increased risk for SBI in patients under 65 years of age. SBI, a cerebrovascular disease, has an age-dependent nature. The causes of SBI are multifactorial, and additional environmental risk factors of SBI may develop with age. In this study, logistic regression, adjusting for possible confounders such as age, hypertension, and diabetes mellitus, showed a significant relationship between the 1298A\>C polymorphism and early-onset SBI under 65 years of age. Prior to this study, Kohara, et al.[@B2] reported that the *MTHFR* 677TT genotype is an independent risk factor for SBI and white matter lesions in the general Japanese population, especially in elderly subjects over 60 years of age. Since genetic polymorphisms often vary among ethnic groups or geographical areas, further studies are needed to clarify the association between *MTHFR* polymorphisms and SBI in diverse ethnic populations.

This study has limitations because it was conducted in a hospital-based population. The other possible limitations are related to exposure to different environmental factors, such as daily folate intake, additional genetic effects such as methionine synthase (MTR) and methionine synthase reductase (MTRR), and ethnic differences. Large, community-based random sampling is needed in order to resolve these limitations.

Despite these limitations, this study is unique in that it focused on the relationship between the *MTHFR* 1298A\>C polymorphism and SBI in a Korean population. This study presents evidence that the 1298A\>C polymorphism, but not the 677C\>T polymorphism, acts as an independent risk factor for SBI, especially in patients under 65 years of age. In addition, it indicates that the polymorphisms of *MTHFR* 677C\>T and 1298A\>C interact additively, resulting in an increased risk of SBI in a Korean population.
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###### 

Baseline Characteristics in Silent Brain Infarction (SBI) Patients and Control Subjects
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*p*-values are Chi-square test for categorical data, and two sample t-test for the continuous data.

^\*^Values are mean ± SD (standard deviation).
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Comparison of Genotype Frequencies in the *MTHFR* 677C\>T and 1298A\>C Polymorphisms between Patients with Silent Brain Infarction (SBI) and Control Subjects
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AOR, adjusted odds ratios (adjusted by age, gender, hypertension, diabetes mellitus, and hyperlipidemia); MTHFR, methylenetetrahydrofolate reductase.
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Comparison of Genotype Frequencies in the *MTHFR* 1298A\>C Polymorphism between Patients with Silent Brain Infarction (SBI) and Control Subjects, Stratified by Sex and Age

![](ymj-51-253-i003)

AOR, adjusted odds ratios (adjusted by age, gender, hypertension, diabetes mellitus and hyperlipidemia); MTHFR, methylenetetrahydrofolate reductase.

^\*^*p* \< 0.05.
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Comparison of Haplotype Frequencies in the *MTHFR* 677C\>T and 1298A\>C Polymorphisms between Patients with Silent Brain Infarction (SBI) and Control Subjects
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MTHFR, methylenetetrahydrofolate reductase.

*p*-values are calculated by the permutation test.

###### 

Levels of Plasma Total Homocysteine According to *MTHFR* 677C\>T and 1298A\>C Genotypes in SBI Patients and Control Subjects
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MTHFR, methylenetetrahydrofolate reductase.

^\*^Mean ± standard error.

*p* values are calculated by an analysis of covariance (ANCOVA). Homocysteine levels are adjusted by age and gender.
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